Fecal calprotectin in inflammatory bowel disease

Clinical and Experimental Gastroenterology

Volumn 9, Issue , 2016, Pages 21-29

  Walsham, Natalie E ^a   Sherwood, Roy A ^b  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Calprotectin; Crohn s disease; Inflammation; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; CALGRANULIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL ASSESSMENT; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC KIT; DIGESTIVE SYSTEM INFLAMMATION; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FECES LEVEL; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; PATIENT MONITORING; REVIEW; TREATMENT RESPONSE; TURBIDIMETRY; ULCERATIVE COLITIS;

EID: 84960377463     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S51902     Document Type: Review

References (76)

1. National Institute for Health and Clinical Excellence. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. NICE diagnostic guideline 11. London UK. 2013.
2. Fagerhol M, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 1980;16(Suppl):273-282.
3. Hsu K, Champaiboon C, Guenther BD, et al. Anti-infective protective properties of S100 calgranulins. Antiinflamm Antiallergy Agents Med Chem. 2009;8:290-305.
4. Roseth A, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by fecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:276-180.
5. Roseth A, Schmidt P, Fagerhol M. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50-54.
6. Roseth A, Fagerhol M, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-798.
7. Lasson A, Stotzer PO, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26-32.
8. Husebye E, Tøn H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001;96:2683-2687.
9. Calafat M, Cabré E, Manosa M, Lobatón T, Marín L, Domènech E. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: What is the best timing for stool sampling? Inflamm Bowel Dis. 2015;21:1072-1076.
10. Naismith GD, Smith LA, Barry SJ, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn’s disease. Aliment Pharmacol Ther. 2013;37:613-621.
11. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr. 2002;34: 323-324; author reply 324-325.
12. Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014;2:30-37.
13. Kok L, Elias SG, Witteman BJ, et al. Diagnostic accuracy of point-of- care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study. Clin Chem. 2012;58:989-998.
14. Whitehead SJ, French J, Brookes MJ, Ford C, Gama R. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem. 2013;50:53-61.
15. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterol. 2002;123:450-460.
16. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41(1): 56-66.
17. Von Roon A, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803-813.
18. Van Rheenen P, Van de Vijvier A, Fidler V. Faecal calprotectin for screening for patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Brit Med J. 2010;341:c3369.
19. Degraeuwe PL, Beld MP, Ashorn M, et al. Faecal calprotectin in suspected paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2015;60:339-346.
20. Henderson P, Anderson N, Wilson D. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637-645.
21. Burri E, Manz M, Schroeder P, et al. Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness. BMC Gastroenterology. 2014;14:57.
22. Pavlidis P, Chedgy FJQ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scand J Gastoenterol. 2013;48:1048-1054.
23. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos G. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP and clinical indices. Am J Gastroenterol. 2008;103:162-169.
24. Schoepfer AM, Beglinger C, Strauman A, et al. Fecal calprotectin corre- lates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, leukocytes and the CDAI. Am J Gastroenterol. 2010;105:162-169.
25. Schoepfer AM, Beglinger C, Strauman A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin and blood leukocytes. Inflamm Bowel Dis. 2013;19:332-341.
26. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-46.
27. Lobatón T, López-García A, Rodríguez-Moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis. 2013;7:e641-e651.
28. Sauter B, Beglinger C, Girardin M, et al. Monitoring disease activity and progression in Crohn’s disease. A Swiss perspective on the IBD Ahead ‘Optimised Monitoring’ recommendations. Digestion. 2014;89:299-309.
29. Schoepfer SM, Vavricka S, Zahnal-Straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis. 2012;6:412-418.
30. Roseth A, Aadland E, Grzyb K. Normalization of fecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scan J Gastroenterol. 2004;39:1017-1020.
31. D’Haens G, Fernante M, Vermiere S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218-2224.
32. Burri E, Beglinger C, von Felten S, Lehmann FS. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci. 2015;60:485-491
33. Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis. 2008;14:1392-1398.
34. De Vos M, Dewit O, D’Haens G, et al. Fast and sharp decline in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis. 2012;6:557-562.
35. Molander P, Af Björkestein C, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017.
36. Ho G, Lee H, Brydon G, Ting T, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673-678.
37. Molander P, Färkkilä M. Ristimäki A, et al. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2015;9:33-40.
38. Theede K, Kiszka-Kanowitz M, Mertz Nielsen A, Nordgaard-Lassen I. The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment. Scand J Gastroenterol. 2014;49:418-423.
39. Kolho K, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoids therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:720-725.
40. Kolho K, Sipponen T. The long-term outcome of anti-tumour necrosis factor-α therapy related to fecal calprotectin values during induction therapy in paediatric inflammatory bowel disease. Scan J Gastroenterol. 2014;49:434-446.
41. Colombel J, Sandborn W, Reinisch W, et al. Infliximab, azothio-prine, or combination therapy for Crohn’s disease. New Eng J Med. 2010;362:1383-1395.
42. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54:364-368.
43. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterol. 2000;119:15-22.
44. Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45: 872-877.
45. D’Incà R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease. Am J Gastroenterol. 2008;103:2007-1014.
46. Gisbert JP, Bermejo F, Perez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190-1198.
47. Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determing histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1229-1235.
48. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669-673.
49. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22:340-345.
50. Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis. 2010;4:144-152.
51. Vos MD, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inlamm Bowel Dis. 2013;19:211-2117.
52. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380:1606-1619.
53. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based concensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis. 2010;4:63-101.
54. Lamb CA, Mohiuddin MK, Gicquel J, et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br J Surg. 2009;96:663-674.
55. Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: a comparison with ultrasound. Eur Rev Med Pharacol Sci. 2006;10:17-22.
56. Yamamoto T, Shiraki M, Bamba T, et al. Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn’s disease after ileocolonic resection: A pro- spective pilot study. United European Gastroenterol J. 2013;1:368-374.
57. Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterol. 2015;148:938-947.
58. Boschetti G, Laidet M, Moussata D, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110:865-872.
59. Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn’s disease. United European Gastroenterol. 2014;3:5-10.
60. Thomas P, Rihani H, Roseth A, et al. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum. 2000;43:214-220.
61. Johnson M, Maestranzi S, Duffy A, et al. Faecal calprotectin: a non-invasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol. 2008;20:174-179.
62. Pakarinen M, Koivusalo A, Natursen J, et al. Fecal calprotectin mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for paediatric-onset ulcerative colitis. Inflamm Bowel Dis. 2010;16:482-486.
63. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402-408.
64. Hoff G, Grotmel T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut. 2004;53:1329-1333.
65. Meucci G, D’Incà R, Maieron R, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicentre prospective study. Dig Liver Dis. 2010;42:191-195.
66. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362-366.
67. Maiden L. Capsule endoscopic diagnosis of nonsteroidal anti-inflammatory drug-induced enteropathy. J Gastroenterol. 2009;44 (Suppl 19):64–71
68. Shastri YM, Bergis D, Povse N, et al. Prospective multicentre study evaluating fecal calprotectin in adult acute bacterial diarrhoea. Sm J Med. 2008;121:1099–1106.
69. Nielsen HL, Engberg J, Ejlertsen T, Nielsen H. Evaluation of fecal calprotectin in Campylobacter concisus and Camplylobacter jejuni/coli gastroenteritis. Scand J Gastroenterol. 2013;48:633–635.
70. Sykora J, Siala K, Humi M, Varvarovská J, Schwarz J, Pomahacová R. Evaluation of faecal calprotectin as a valuable non-invasive marker in distinguishing gut pathogens in young children with acute gastroenteritis. Acta Paediatr. 2010;99:1389–1395.
71. Chen CC, Huang JL, Chang CJ, Kong MS. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhoea and usefulness in evaluating bacterial or viral pathogens in children. J Pediatr Gastroenterol Nutr. 2012;55:541–547.
72. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticulitis: a case-control study. Int J Colorectal Dis. 2009;24:49–55.
73. Tursi A. Biomarkers in diverticular disease of the colon. Dig Dis. 2012;30:12–18.
74. Sherwood RA. Faecal markers of gastrointestinal inflammation. J Clin Path. 2012;65:981–985.
75. Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Ther Adv Gastroenterol. 2015;8:23–36.
76. Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measurement of fecal calprotectin in the diagnosis of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:253–262.